Abstracts tagged "Auto-immunity"

Abstract Number: 020 • 2020 Pediatric Rheumatology Symposium
Murine Roseolovirus Induces Autoimmune Disease and Development of Autoantibodies
Tarin Bigley¹ and Wayne Yokoyama ², ¹Washington University in St. Louis, Saint Louis, Missouri, ²Washington University in St. Louis, St Louis, Missouri
Background/Purpose: Murine roseolovirus (MRV) is a recently sequenced beta-herpesvirus that is a natural murine pathogen and is genetically highly related to HHV6 and HHV7. The…
Abstract Number: 975 • 2019 ACR/ARP Annual Meeting
Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function
Abhimanyu Amarnani¹, Ramile Dilshat ², Nikita Malakhov ³, Brian Ghezelaiagh ⁴, Chongmin Huan ¹, Erna Magnusdottir ², Eirikur Steingrimsson ² and Christopher Roman ¹, ¹SUNY Downstate Medical Center, Brooklyn, ²University of Iceland Biomedical Center, Reykjavik, Iceland, ³SUNY Downstate Medical Center, New York Presbyterian-Weill Cornell Medical Center, Brooklyn, ⁴SUNY Downstate Medical Center, Stony Brook University, Brooklyn
Background/Purpose: Autoreactive B cells are central in the development of many autoimmune diseases, such as systemic lupus erythematosus (SLE), and are normally eliminated or inactivated…
Abstract Number: 1810 • 2019 ACR/ARP Annual Meeting
Rheumatic Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study
Céline Anquetil¹, Olivier Benveniste ¹, Javid ‎ Moslehi ², Douglas Johnson ², Bénédicte lebrun-vignes ¹, Olivier Lambotte ³, Joe-Elie Selam ⁴, Jean-Philippe Spano ⁵ and Yves Allenbach ¹, ¹Sorbonne Université, Paris, France, ²Vanderbilt, Nashville, ³APHP Médecine Interne/Immunologie Clinique, Hôpital Bicêtre, Paris, France. Université Paris Sud 11 – INSERM U1184 - CEA, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Paris, France, ⁴Sorbonne université, Paris, ⁵Sorbonne Université, Paris, French Guiana
Background/Purpose: Monoclonal antibodies targeting co-inhibitory immune checkpoints (PD-1/PDL1 axis or CTLA-4) showed unprecedented clinical activity in several types of cancer by restoring antitumor immune responses.…
Abstract Number: 2618 • 2019 ACR/ARP Annual Meeting
Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients
Michael Mahler¹, Fabrece Roup ¹, Chelsea Bentow ¹, Marie Hudson ², Murray Baron ³, May Choi ⁴ and Marvin Fritzler ⁵, ¹Inova Diagnostics, San Diego, CA, ²Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, Canada, ⁴Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important diagnostic and prognostic role in…
Abstract Number: L07 • 2018 ACR/ARHP Annual Meeting
VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study
Marius Albulescu¹, Ulf Müller-Ladner², Rachel Moate³, Kate Middleton³, Liangwei Wang⁴, Jorn Drappa⁴ and Gabor Illei⁵, ¹Clinical Development, MedImmune, Cambridge, UK, Cambridge, United Kingdom, ²Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ³MedImmune, Cambridge, UK, Cambridge, United Kingdom, ⁴Viela Bio, Gaithersburg, USA, Gaithersburg, MD, ⁵Viela Bio, Gaithersburg, USA, Gaithersberg, MD
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production and plays a central role in RA and other autoimmune diseases. VIB4920 (formerly MEDI4920)…
Abstract Number: 3 • 2018 ACR/ARHP Annual Meeting
Interferon-Alpha Disrupts DNA-Specific B Cell Tolerance in 3H9 Mice
Dario Ferri¹, Yuriy Baglaenko², Ariana Karanxha¹, Kieran Manion¹, Carolina Grajales¹ and Joan E. Wither¹, ¹Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Biomedical Informatics, Brigham Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A central mediator of Systemic Lupus Erythematosus (SLE) pathogenesis is interferon-alpha (IFNα), which is elevated in the serum of SLE patients. IFNα has been…
Abstract Number: 5 • 2018 ACR/ARHP Annual Meeting
Short Chain Fatty Acid Acetate Induces Regulatory B Cells in Mice and Humans, Which Can Protect Against Arthritis
Claire I. Daien^1,2,3, Julie Mielle^1,4, Rachel Audo^1,2,5, Lake-Ee Quek¹, James Krycer¹, Gauthier Rathat⁶, Gabriela Pinget¹, Sumaiya Hoque⁷, Charles Mackay⁸, Jian Tan⁹ and Laurence Macia¹, ¹Charles Perkins Centre, The University of Sydney, Sydney, Australia, ²IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁴IGMM CNRS UMR5535, Montpellier, France, ⁵Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁶Arnaud-de-Villeneuve Hospital, Montpellier, France, ⁷Charles Perkins Centre, The University of Sydney, Sydney, France, ⁸Monash University, Melbourne, Australia, ⁹Charles Perkins Centre, The University of Sydney, Montpellier, Australia
Background/Purpose: Autoimmunity and more broadly non-communicable diseases develop with the imbalance between anti- and pro-inflammatory immune cell subsets, leading to an uncontrolled and damaging inflammation.…
Abstract Number: 142 • 2018 ACR/ARHP Annual Meeting
Peripheral CD4+CD25+Foxp3+T Regulatory Cells Absolutely Reduce in Patients with Systemic Lupus Erythematosus
Xiao-Qing Liu¹, Na-Lin Lai², Yanan Duan¹, Junwei Chen¹, Xiao-Feng Li³ and Chong Gao⁴, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Regulatory T (Treg) cells, with the capacity to suppress immune responses, and effector T (Teff) cells, to promote inflammation, have been intensively studied in…
Abstract Number: 1382 • 2018 ACR/ARHP Annual Meeting
Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine
Rebecca Gaffney¹ and Victoria P. Werth², ¹Dermatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: QuantiFERON-TB Gold is commercial interferon-γ release assay used to screen patients for tuberculosis before starting or while on immunosuppressive therapies. Clinical studies on efficacy…
Abstract Number: 1968 • 2018 ACR/ARHP Annual Meeting
eQTL Analysis of More Than 1000 Human Blood Samples Reveals Shared and Unique Signals across Seven Systemic Autoimmune Diseases : The Precisesads Project
Martin Kerick¹, David Gonzalez Serna¹, Elena Carnero-Montoro², Sepideh Babaei³, Marialbert Acosta-Herrera¹, Maria Teruel², Guillermo Barturen², Zuzanna Makowska³, Anne Buttgereit⁴, Sikander Hayat⁴, Jorge Kageyama⁴, Manuel Martínez-Bueno², PRECISESADS Clinical Consortium⁵, Ralf Lesche³, Javier Martin⁶ and Marta Alarcón-Riquelme², ¹Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain, ²Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany, ⁴Bayer Pharma Aktiengesellschaft, Berlin, Germany, ⁵Spain, ⁶Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain., Granada, Spain
Background/Purpose: Systemic autoimmune diseases (SADs) are chronic inflammatory conditions with autoimmune aetiology and many common clinical features, hampering diagnosis and adequate treatment decisions. Finding new…
Abstract Number: 2093 • 2018 ACR/ARHP Annual Meeting
Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency Worsens Autoimmunity in the Lyn-Deficient Murine Model of Lupus By Disinhibiting the Type I Interferon (IFN) Pathway
Champa Nataraja¹, Eric Morand¹, Jacinta Lee¹, Taylah Bennett¹, Jacqueline Flynn¹, James Harris¹ and Sarah Jones², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease associated with B cell hyperactivity driven by dysregulated type I IFN. Lyn-deficient mice develop lupus-like…
Abstract Number: 2932 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology
Eric Grund¹, Lixia Zhang¹, Leonardo Rodrigues¹, Viatcheslav Akmaev¹, Rangaprasad Sarangarajan¹, Michael Kiebish¹, Niven Narain¹ and Gary S. Gilkeson², ¹BERG, LLC, Framingham, MA, ²Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Biomarkers for use in developing treatments and diagnostics for Systemic Lupus Erythematosus (SLE) are a large unmet need. The wide differential in patient progression…
Abstract Number: 492 • 2017 ACR/ARHP Annual Meeting
Is Leukotoxin_A Produced By Aggregatibacter Actynomycetemcomitans Important for Initiating Autoimmune Responses Underlying Rheumatoid Arthritis?
Mikhail Volkov¹, Jacqueline Dekkers¹, Bruno G. Loos², Sergio Bizzarro², Tom W.J. Huizinga³, Helle A. Praetorius⁴, Rene E.M. Toes⁵ and Diane van der Woude¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Periodontology, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit, Amsterdam, Netherlands, ³Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁴Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In a recent publication in Science Translational Medicine, Konig et al. (2016) describe a potential explanation for the link between periodontal infection and RA.…
Abstract Number: 562 • 2017 ACR/ARHP Annual Meeting
Anti-Muscarinic Receptor 3 Antibodies – a Cross Reactive Result of Ro60 Immunization
Syed M.S. Quadri¹, Biji T Kurien², Kristi A. Koelsch³ and R. Hal Scofield⁴, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Okalahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjogren’s syndrome (SS) is a chronic autoimmune inflammatory disease characterized by impaired function of salivary and lacrimal glands leading to dry mouth and dry…
Abstract Number: 1319 • 2017 ACR/ARHP Annual Meeting
TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases
Hiroaki Hayashi, Ryuusuke Kaneko, Manabu Tayama, Shunsuke Demizu, Daichi Akasaka, Hiroki Irie, Aki Kawagishi, Yoshio Ogino, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: Spleen tyrosine kinase (Syk) is a non-receptor cytoplasmic tyrosine kinase. B-cell receptor (BCR) and Fc receptor-mediated syk signaling pathways lead to activation of several…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].